UK markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.53-0.15 (-0.85%)
At close: 04:00PM EDT
17.53 +0.00 (+0.00%)
After hours: 04:15PM EDT

Kura Oncology, Inc.

12730 High Bluff Drive
Suite 400
San Diego, CA 92130
United States
858 500 8800
https://kuraoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 142

Key executives

NameTitlePayExercisedYear born
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President1.22MN/A1969
Ms. Kathleen FordChief Operating Officer824.95kN/A1947
Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainN/AN/AN/A
Ms. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementN/AN/AN/A
Dr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentN/AN/AN/A
Mr. Brian T. Powl M.B.A., M.S.Chief Commercial OfficerN/AN/A1974
Dr. Francis J. Burrows Ph.D.Senior Vice President of Translational ResearchN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Corporate governance

Kura Oncology, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.